CGEM — Cullinan Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1789972 ·
Last close
$16.50
Market Cap
$1.01B
52W High
$19.43
52W Low
$11.68
ADV30
900,468
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -53,697,000 | -49,661,000 | 402,984,000 | 75,081,000 | 36,812,000 |
| Dec 2025 | 0 | — | -55,259,000 | -50,713,000 | 448,374,000 | 88,332,000 | 39,644,000 |
| Sep 2025 | 0 | — | -55,595,000 | -50,610,000 | 484,126,000 | 103,335,000 | 32,757,000 |
| Jun 2025 | 0 | — | -75,798,000 | -70,055,000 | 520,329,000 | 72,820,000 | 28,183,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-175,750,000
Investing CF
$179,989,000
Financing CF
$1,088,000
CapEx
$-11,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.35
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-588,119,000
Inventory
—
Receivables
—
ST Investments
$289,564,000
EBIT TTM
$-241,648,000
Pretax Income TTM
$-219,879,000
Interest Exp TTM
—
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -241,648,000 | -219,879,000 | 448,374,000 | 39,644,000 | — | -175,750,000 |
| Dec 2024 | 0 | -196,919,000 | -167,383,000 | 621,824,000 | 31,496,000 | — | -145,303,000 |
| Dec 2023 | 0 | -190,649,000 | -153,162,000 | 484,182,000 | 30,287,000 | — | -134,275,000 |
| Dec 2022 | 0 | -132,137,000 | 111,214,000 | 561,117,000 | 26,088,000 | — | -126,664,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.53
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MGTX | MeiraGTx Holdings plc | $1.09B | $11.79 | — |
| REPL | Replimune Group, Inc. | $940.19M | $11.20 | — |
| ODTX | Odyssey Therapeutics, Inc. | $909.23M | $18.93 | — |
| VOR | Vor Biopharma Inc. | $1.15B | $21.15 | — |
| SANA | Sana Biotechnology, Inc. | $871.05M | $3.13 | — |
News headlines (Yahoo Finance, 1h cache)
Cullinan Therapeutics (CGEM) Advances CLN 049 After FDA Feedback, Is The Upside Already Priced In?
2026-07-30 00:16 · Yahoo
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
2026-07-28 11:00 · Yahoo
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone
2026-07-02 22:40 · Yahoo
Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes
2026-06-23 09:06 · Yahoo
Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing
2026-06-22 15:40 · Yahoo
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
2026-06-10 11:30 · Yahoo
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
2026-06-06 09:15 · Yahoo
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
2026-05-26 11:00 · Yahoo
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
2026-05-19 11:00 · Yahoo
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
2026-05-18 21:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.